Ozempic vs Mounjaro: Differences, Dosing, and Which Is Better for Type 2 Diabetes
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both once-weekly type 2 diabetes injections, but they are different molecules from different makers. In SURPASS-2, tirzepatide beat injectable semaglutide on A1C and weight, while only Ozempic carries a chronic kidney disease indication.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Ozempic and Mounjaro are both once-weekly injections for type 2 diabetes, but they are different drugs: Ozempic is semaglutide, made by Novo Nordisk and first approved by the FDA on December 5, 2017, while Mounjaro is tirzepatide, made by Eli Lilly and first approved on May 13, 2022 [1][3][4]. Neither one is simply “better.” In the one published head-to-head trial, tirzepatide lowered A1C and body weight more than injectable semaglutide [4][8], but only Ozempic is FDA-approved to protect the kidneys in people with type 2 diabetes and chronic kidney disease, an indication granted on January 28, 2025 [1][3]. Which drug fits a given person depends on their other conditions, age, insurance, and how they respond, and that choice belongs with a clinician.
The two drugs also work differently at the receptor level. Semaglutide is an analog of the naturally occurring hormone GLP-1; it stimulates insulin secretion and lowers glucagon secretion when blood glucose is high [3]. Tirzepatide is a single molecule that activates receptors for two natural incretin hormones, GIP and GLP-1, and Lilly describes Mounjaro as the first and only FDA-approved GIP and GLP-1 receptor agonist [4][5].
What are the basic differences between Ozempic and Mounjaro?
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly [3][4] |
| Drug class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist [1][2] |
| First FDA approval | December 5, 2017 | May 13, 2022 [3][4] |
| How it’s taken | Once-weekly injection under the skin | Once-weekly injection under the skin [1][2] |
| Approved ages | Adults | Adults and children 10 and older [1][2] |
Both are injected subcutaneously once a week, at any time of day, with or without meals [1][2][7].
What is each drug FDA-approved to treat?
Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [1][3]. It also carries two risk-reduction indications: reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease, approved January 16, 2020 [1][3]; and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, approved January 28, 2025 [1][3]. Novo Nordisk announced that approval as making Ozempic the only GLP-1 receptor agonist with the kidney indication [3].
Mounjaro is approved to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes [2][4][7]. Its cardiovascular indication, approved August 28, 2026, covers reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events [2][4][5].
Neither Ozempic nor Mounjaro is approved for weight loss [1][2][3][4]. The weight-loss brand versions of the same molecules are Wegovy (semaglutide, approved June 4, 2021) and Zepbound (tirzepatide, approved November 8, 2023) [3][8]. Ozempic tablets, a separate oral form of semaglutide rebranded from Rybelsus on January 30, 2026, are also distinct from the injection [3].
How do the dosing schedules compare?
The FDA labels describe different ladders for each drug, and the milligram strengths do not translate between them. Neither label states any conversion between semaglutide and tirzepatide doses [1][2].
| Ozempic (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|
| Starting dose | 0.25 mg once weekly | 2.5 mg once weekly (for initiation only, not for glycemic control) [1][7] |
| First step up | 0.5 mg weekly after 4 weeks | 5 mg weekly after 4 weeks [1][7] |
| Further increases | 1 mg weekly after at least 4 weeks on 0.5 mg; 2 mg weekly after at least 4 weeks on 1 mg | 2.5 mg increments after at least 4 weeks on the current dose [1][2][7] |
| Maximum dose | 2 mg once weekly | Adults: 15 mg weekly; pediatric patients 10 and older: 10 mg weekly [1][2][7] |
| Available strengths | 0.25 mg, 0.5 mg, 1 mg, 2 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg [2][7] |
For the kidney and cardiovascular-death risk reduction indication, the Ozempic label states the dosage is increased to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose [1]. The 2 mg Ozempic dose was FDA-approved on March 28, 2022 [3].
The missed-dose rules differ. For Ozempic, a missed dose is administered within 5 days of the missed dose [1]. For Mounjaro, it is administered as soon as possible within 4 days (96 hours); if more than 4 days have passed, the missed dose is skipped and the next dose is taken on the regularly scheduled day [7]. The Mounjaro weekly dosing day can be changed as long as at least 3 days (72 hours) separate the two doses [7].
Injection sites also differ slightly. Ozempic is injected in the abdomen, thigh, or upper arm [1]. Mounjaro is injected in the abdomen or thigh, or by another person in the back of the upper arm, with sites rotated with each dose [2][7].
Is Mounjaro more effective than Ozempic for lowering A1C?
In SURPASS-2, tirzepatide achieved superior A1C and body weight reductions compared with injectable semaglutide across all three tirzepatide doses studied, in adults with type 2 diabetes [4][8]. The results were published in the New England Journal of Medicine and reported June 25, 2021 [4][8]. The available sources describe the comparator only as injectable semaglutide and do not specify its dose.
That trial is the main direct comparison, but it does not settle every question. SURPASS-CVOT, the first cardiovascular outcomes trial to compare two incretin medicines head-to-head rather than against placebo, tested Mounjaro (15 mg or the maximum tolerated dose) against Trulicity (dulaglutide) 1.5 mg, not against Ozempic [5]. It enrolled 13,299 participants randomized 1:1 across 640 sites in 30 countries, with a median follow-up of 210.1 weeks (about four years) [5]. Mounjaro showed an 8% lower rate of MACE-3 with a hazard ratio of 0.92 (95.3% CI: 0.83, 1.01), meaning it was non-inferior to dulaglutide, but superiority was not established [5]. Ozempic’s own cardiovascular and kidney outcomes trials are reflected in label sections 14.2 and 14.3 of its prescribing information [1].
Which one is approved for children?
Only Mounjaro is approved for patients younger than 18. Its glycemic control indication covers pediatric patients 10 years of age and older, a change the label lists under Recent Major Changes dated 12/2025 [2][7]. Ozempic’s glycemic control indication covers adults only [1][3].
The pediatric approval was based on SURPASS-PEDS, which studied 99 patients age 10 and older, all already on metformin, basal insulin, or both, randomized to tirzepatide 5 mg, 10 mg, or placebo for 30 weeks [6]. Mean A1C fell 2% from baseline (pooled doses), a mean difference of −1.8% versus placebo, and BMI fell a mean of 8.8 kg/m² from baseline, a mean difference of −8.3 kg/m² versus placebo [6]. The results were published in The Lancet, volume 406, issue 10511, pages 1484–1496 [6]. Side effects were consistent with those in adults, though rates of vomiting, abdominal pain, and hypoglycemia appear higher in pediatric patients [6].
How do the side effects compare?
The common side effect lists overlap heavily. For Ozempic, the most common adverse reactions reported in at least 5% of patients are nausea, vomiting, diarrhea, abdominal pain, and constipation [1][3]. For Mounjaro, they are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain [2][4][7].
Both drugs carry the same boxed warning: rodent studies show thyroid C-cell tumors, and it is unknown whether either drug causes such tumors, including medullary thyroid carcinoma, in humans [1][2][7]. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in people with serious hypersensitivity to the drug or its excipients [1][2][7]. Both labels also state that routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection [1][7].
The shared warnings and precautions are nearly identical: acute pancreatitis, hypoglycemia when combined with insulin or an insulin secretagogue, hypersensitivity reactions, acute kidney injury from volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation [1][2][7]. Neither drug is recommended in patients with severe gastroparesis [1][2][7]. The Severe Gastrointestinal Adverse Reactions warning was added to the Ozempic label in 10/2025 and to the Mounjaro label in 12/2025 [1][2].
What about drug interactions, birth control, and pregnancy?
Both drugs delay gastric emptying and can affect the absorption of oral medications taken at the same time; the Ozempic label says to use oral medications with caution [1][2][7].
The labels differ on reproductive guidance. The Ozempic label states it should be discontinued in women at least 2 months before a planned pregnancy, because of semaglutide’s long washout period [1]. The Mounjaro label states that, based on animal studies, it may cause fetal harm, and advises women using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose escalation [5][7].
On combining drugs, the supplied labeling that addresses stacking is for Zepbound, the tirzepatide weight-loss brand: its limitations of use state that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended [8].
What devices and forms do they come in?
Ozempic comes in single-patient-use pens: 2 mg/3 mL (0.68 mg/mL) delivering four 0.25 mg doses plus two 0.5 mg doses, or four 0.5 mg doses; 4 mg/3 mL (1.34 mg/mL) for four 1 mg doses; and 8 mg/3 mL (2.68 mg/mL) for four 2 mg doses [1][3]. It is also supplied as a single-dose prefilled syringe in 0.25 mg, 0.5 mg, or 1 mg per 0.5 mL [1].
Mounjaro comes in more presentations: a single-dose pen or single-dose vial in 2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL, and a multi-dose vial or single-patient-use KwikPen in 10/20/30/40/50/60 mg per 2.4 mL, each delivering four 0.6 mL weekly doses from 2.5 to 15 mg [2][7]. Vial users need an appropriate syringe, such as a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose, with a new syringe and needle for each injection [7]. The solution should be inspected before use and appear clear and colorless to slightly yellow [7].
Neither pen should ever be shared between patients, even if the needle is changed [1][2]. Training on injection technique is required before first use for both, and self-injection is allowed if a healthcare provider determines it is appropriate [5][7].
What do Ozempic and Mounjaro cost?
On August 18, 2025, Novo Nordisk announced it lowered the cost of Ozempic to $499 per month for self-paying patients [3]. On February 24, 2026, Novo Nordisk announced a significant reduction in the US list price for Wegovy, Ozempic, and Rybelsus, without stating the new price in the available source [3]. On March 9, 2026, Novo Nordisk announced expanded US access to its semaglutide medicines through Hims & Hers [3]. On the tirzepatide side, on June 16, 2025, Lilly announced it would offer all approved doses of Zepbound single-dose vials through LillyDirect self-pay pharmacy solutions [8].
How do doctors choose between them?
The labels themselves point to where the drugs diverge. Only Ozempic has the chronic kidney disease indication in type 2 diabetes [1][3]. Only Mounjaro is approved for patients as young as 10 [2][4]. The cardiovascular indications differ in scope: Ozempic’s covers adults with established cardiovascular disease, while Mounjaro’s covers adults at high risk for cardiovascular events [1][2]. Lilly states that Mounjaro is the #1 most prescribed branded type 2 diabetes medicine for adults in the US, and that as many as 1 in 3 US adults with type 2 diabetes may have undetected cardiovascular disease [5]. Device preference can also matter, since Mounjaro offers vial and KwikPen options Ozempic does not [1][2]. Dose selection and switching decisions rest with a prescriber, and no conversion between the two drugs’ milligram strengths exists in either label [1][2].
Sources
- Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. Prescribing information.
- National Library of Medicine, DailyMed. MOUNJARO (tirzepatide) injection, solution. Drug label.
- Drugs.com. Ozempic (semaglutide) FDA Approval History. April 23, 2026.
- Drugs.com. Mounjaro (tirzepatide) FDA Approval History. September 10, 2026.
- Drugs.com. FDA Approves Lilly’s Mounjaro (tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes. August 28, 2026.
- Pediatric Endocrine Society. New Meds and Tech: Mounjaro (tirzepatide) approved in Pediatrics. February 24, 2026.
- US Food and Drug Administration. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing information.
- Drugs.com. Zepbound (tirzepatide) FDA Approval History. February 24, 2026.
- Academy of Managed Care Pharmacy. Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s.
- Novo Nordisk, NovoCare. Ozempic pill and pen price guide.
Frequently asked questions
Is Mounjaro stronger or more effective than Ozempic for lowering A1C?
In SURPASS-2, tirzepatide achieved superior A1C and body weight reductions compared with injectable semaglutide across all three tirzepatide doses studied in adults with type 2 diabetes. The results were published in the New England Journal of Medicine and reported June 25, 2021.
Can you switch from Ozempic to Mounjaro, and do the mg doses translate?
Neither FDA label provides a conversion between semaglutide and tirzepatide doses, so there is no mg-for-mg translation. Ozempic doses run 0.25 mg to 2 mg weekly, while Mounjaro doses run 2.5 mg to 15 mg weekly in adults. Any switch and the starting dose after it are decisions for a prescriber.
Which one is approved for kids?
Only Mounjaro. It is approved to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes, based on the SURPASS-PEDS trial of 99 patients. Ozempic's glycemic control indication covers adults only. The maximum pediatric Mounjaro dose is 10 mg once weekly.
Which one protects the kidneys or the heart?
Both carry cardiovascular risk-reduction indications, but only Ozempic has a kidney indication. On January 28, 2025, the FDA approved Ozempic to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Mounjaro's cardiovascular indication was approved August 28, 2026.
Are the side effects different between the two?
They overlap heavily. Ozempic's common reactions (at least 5% of patients) are nausea, vomiting, diarrhea, abdominal pain, and constipation; Mounjaro's are the same list plus decreased appetite and dyspepsia. Both carry the same boxed warning for rodent thyroid C-cell tumors and the same core warnings, including pancreatitis, hypoglycemia with insulin, and severe GI reactions.
Can either be prescribed for weight loss, and what are Wegovy and Zepbound?
Neither Ozempic nor Mounjaro carries a weight-loss indication. The same molecules are sold for weight management under different brand names: Wegovy (semaglutide), first approved June 4, 2021, and Zepbound (tirzepatide), first approved November 8, 2023.
What happens if you miss a weekly dose of each?
For Ozempic, the label says to administer the missed dose within 5 days of the missed dose. For Mounjaro, it says to administer as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip the dose and resume the regular schedule. Mounjaro's dosing day can be changed if at least 3 days (72 hours) separate doses.
Can you take both, or one plus another GLP-1?
The supplied labeling that addresses this is for Zepbound, the tirzepatide weight-loss brand, whose limitations of use state that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.